Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry.
Jurgen SotaDonato RiganteRolando CimazMarco CattaliniMicol FrassiRaffaele MannaLudovico Luca SicignanoElena VerrecchiaEmma AragonaMaria Cristina MaggioGiuseppe LopalcoGiacomo EmmiPaola ParronchiAlberto CauliEwa Więsik-SzewczykJosé Hernández-RodríguezCarla GaggianoMaria TarsiaMariam MourabiGaafar RagabAntonio VitaleClaudia FabianiBruno FredianiVittoria LamacchiaAlessandra RenieriLuca Cantarininull nullPublished in: Rheumatology (Oxford, England) (2021)
IL-1 inhibitors display an excellent long-term effectiveness in terms of DRR, and their survival is not influenced by the biologic line of treatment. They display a favourable safety profile, which deserves, however, a close monitoring given its impact on treatment continuation. Special attention should be paid to molecular diagnosis and mutation penetrance, as patients carrying low-penetrance variants are more likely to interrupt treatment.